Q3 Beat and F-35 Order Add Positives, but Missile Proof Points Still Missing

What happened

Lockheed Martin's third-quarter earnings per share of $7.97 beat Wall Street estimates, and the company announced a Pentagon deal to produce 850 F-35 jets, which sent a positive signal to investors. This comes after the stock had already rallied strongly in July 2026 on missile demand, reaching $582.6 and prompting a WAIT rating in the prior DeepValue report due to valuation and execution concerns. The new F-35 order could stabilize the Aeronautics segment, which had been a source of repeated profit adjustments, but the master report's required catalysts—funded PAC-3 awards and sustained MFC margins above 14%—are not yet confirmed by this news. The Q3 beat supports the earnings trajectory, but the company's fixed-price risks and lumpy cash flow remain. Investors should treat this news as a positive development that reduces some downside risk but does not eliminate the need for missile-related proof points.

Implication

Investors should view the Q3 earnings beat as confirming operational strength, but the primary thesis driver remains missile backlog conversion into funded awards, which is still unconfirmed. The F-35 deal for 850 jets likely spans multiple years and may not immediately improve Aeronautics margins, which have been depressed by F-16 and C-130 charges. At current valuation multiples (21x earnings, 19.5x EV/EBITDA), the stock is not cheap, and the market may be pricing in perfect execution. A disciplined approach would wait for evidence of funded PAC-3 awards and sustained MFC margin above 14% before adding positions. Until then, the WAIT rating remains appropriate, with an attractive entry near $545 and trim level above $650.

Thesis delta

The thesis shifts slightly positive due to the F-35 order providing a potential anchor for Aeronautics, which was the weakest segment. However, the core investment case still hinges on missile-demand proof points: funded PAC-3 awards and MFC margins above 14%. The F-35 deal alone does not change the valuation or the fixed-price execution risk, so the overall rating remains WAIT.